LG-100754 (CD-3159; UVI-2112) is a novel and potent retinoic acid receptors antagonist & agonist or RXR dimers modulater. Specifically, it acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
Physicochemical Properties
| Molecular Formula | C26H36O3 |
| Molecular Weight | 396.57 |
| Exact Mass | 396.266 |
| CAS # | 180713-37-5 |
| PubChem CID | 6442223 |
| Appearance | White to off-white solid powder |
| Density | 1.003g/cm3 |
| Boiling Point | 549.4ºC at 760 mmHg |
| Flash Point | 178.5ºC |
| Vapour Pressure | 6.63E-13mmHg at 25°C |
| Index of Refraction | 1.526 |
| LogP | 6.814 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 29 |
| Complexity | 665 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CCCOC1=CC2=C(C=C1/C(=C\C=C\C(=C\C(=O)O)\C)/C)C(CCC2(C)C)(C)C |
| InChi Key | HNODNXQAYXJFMQ-LQUSFLDPSA-N |
| InChi Code | InChI=1S/C26H36O3/c1-8-14-29-23-17-22-21(25(4,5)12-13-26(22,6)7)16-20(23)19(3)11-9-10-18(2)15-24(27)28/h9-11,15-17H,8,12-14H2,1-7H3,(H,27,28)/b10-9+,18-15+,19-11- |
| Chemical Name | (2E,4E,6Z)-3-methyl-7-(5,5,8,8-tetramethyl-3-propoxy-6,7-dihydronaphthalen-2-yl)octa-2,4,6-trienoic acid |
| Synonyms | LG100754 UVI2112 CD3159 LG-100754 CD-3159 UVI-2112 CD-3159 CD 3159 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | One specific activator of endogenous RXR heterodimers is LG100754 [1]. In mature adipocytes, TNFα-mediated insulin resistance can also be ameliorated by LG100754 [1]. Genuine activation of the endogenous RXR:PPARγ heterodimer and modulation of insulin-dependent signaling pathways are exhibited by LG100754 [1]. |
| ln Vivo | The fact that LG100754 (100 mg/kg) totally prevents the rise in glucose levels suggests that LG100754 can help the body become more insulin resistant [1]. |
| References |
[1]. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~252.17 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.30 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5216 mL | 12.6081 mL | 25.2162 mL | |
| 5 mM | 0.5043 mL | 2.5216 mL | 5.0432 mL | |
| 10 mM | 0.2522 mL | 1.2608 mL | 2.5216 mL |